| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
79 |
| Employees |
200 |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
-35 |
| Cash Flow (TTM) (Millions $) |
36 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Taiwan Liposome Company (TLC) Ltd is a fully-integrated specialty pharmaceutical company located in Taiwan that focuses on the research, development, manufacturing, and commercialization of liposome-based drugs. They have successfully developed innovative liposome-based drug delivery systems, and their technologies have been recognized as one of the world's leading drug delivery platforms.
TLC was established in 1997 and has since made significant advancements in the field of drug delivery systems. They have a team of experienced scientists and researchers who continuously strive to develop new and better liposome-based drug products to serve the unmet medical needs of patients. The company has strong capabilities in research and development, quality control, and production, which enable them to ensure the highest level of quality and reliability for their products.
TLCes liposome-based drug delivery system is a well-established technology that has exceptional potential for drug development. The drug delivery system is designed to improve the therapeutic efficacy and safety of drug molecules by encapsulating them in liposomes, which are tiny spheres made of lipids. This innovative drug delivery system has shown effectiveness in improving the circulation time of drugs, targeting specific tissues, reducing the toxicity and side effects of drugs, and improving the bioavailability of poorly soluble drugs.
TLC has developed several unique liposome-based products that have been approved by regulatory agencies such as the US FDA and the Taiwan FDA for various indications. These products include Doxil, an anticancer drug for the treatment of ovarian and breast cancer, and Lipusu, a fungal infection drug for the treatment of systemic candidiasis. They also have a well-developed pipeline of liposome-based products for the treatment of cancer, infectious diseases, and other therapeutic areas.
Apart from their drug development capabilities, TLC has also established themselves as a reliable and professional CDMO (Contract Development and Manufacturing Organization) with a state-of-the-art manufacturing facility. Their manufacturing capabilities support small-scale and large-scale production to meet the needs of their partners and clients globally. The company complies with regulatory standards such as cGMP, ensuring the highest level of quality and safety of their products.
In conclusion, Taiwan Liposome Company Ltd is a highly innovative specialty pharmaceutical company that has a proven track record in developing liposome-based drug delivery systems. Their technology has been recognized as one of the world's leading drug delivery platforms, and they have a strong pipeline of products, including some that have already received regulatory approval, showcasing tremendous potential for the future. Their manufacturing capabilities also position them as an exceptional CDMO, delivering high-quality drugs to clients globally.
Company Address: 11F-1, No. 3 Yuanqu Street Taipei City 11503
Company Phone Number: 2 2655 7377 Stock Exchange / Ticker: NASDAQ TLC
|
%